| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.21.6.905 |
| P698 | PubMed publication ID | 11397695 |
| P50 | author | Thomas Kislinger | Q50420450 |
| P2093 | author name string | D M Stern | |
| Y Lu | |||
| K Olson | |||
| A M Schmidt | |||
| W Qu | |||
| M A Hofmann | |||
| A Taguchi | |||
| V D'Agati | |||
| T Wendt | |||
| N Tanji | |||
| M Pischetsrieder | |||
| L Bucciarelli | |||
| G Cataldegirmen | |||
| L J Ferran | |||
| M Goova | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 905-910 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice | |
| P478 | volume | 21 |
| Q37348392 | A critical appraisal of erectile function in animal models of diabetes mellitus |
| Q28507626 | A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis |
| Q37003623 | AGE restriction in diabetes mellitus: a paradigm shift |
| Q38213275 | AGEs and chronic subclinical inflammation in diabetes: disorders of immune system |
| Q46734928 | AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. |
| Q37760250 | AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? |
| Q39883888 | Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice |
| Q93355257 | Advanced Glycation End Products Stimulate Angiotensinogen Production in Renal Proximal Tubular Cells |
| Q35796793 | Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease |
| Q36069797 | Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation |
| Q46613227 | Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine |
| Q38118993 | Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction |
| Q24563997 | Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells |
| Q35672476 | Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease |
| Q35133201 | Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE). |
| Q37233185 | Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene |
| Q34056610 | Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling |
| Q35661145 | Amphoterin as an extracellular regulator of cell motility: from discovery to disease. |
| Q28303607 | Atherosclerosis and restenosis: is there a role for RAGE? |
| Q39199900 | Beneficial Effect of Glucose Control on Atherosclerosis Progression in Diabetic ApoE(-/-) Mice: Shown by Rage Directed Imaging. |
| Q30360076 | Beneficial effect of low ethanol intake on the cardiovascular system: possible biochemical mechanisms |
| Q47216784 | Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update |
| Q34890522 | Central role of RAGE-dependent neointimal expansion in arterial restenosis |
| Q34778644 | Combinatorial library of improved peptide aptamers, CLIPs to inhibit RAGE signal transduction in mammalian cells. |
| Q52355379 | Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets. |
| Q58122201 | Coronary Microvascular Remodeling in Type 2 Diabetes: Synonymous With Early Aging? |
| Q34350546 | Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature |
| Q37486465 | Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions |
| Q36401585 | Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention |
| Q37941867 | Do statins have a role in reduction/prevention of post-PCI restenosis? |
| Q35674511 | Effects of diabetes on the vascular system: current research evidence and best practice recommendations |
| Q42176457 | Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases. |
| Q36766914 | Endothelial effects of antihypertensive treatment: focus on irbesartan |
| Q48634281 | Exercise Amaliorates Metabolic Disturbances and Oxidative Stress in Diabetic Cardiomyopathy: Possible Underlying Mechanisms. |
| Q37586770 | Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways |
| Q34994616 | Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. |
| Q43266618 | Fructose and moderately high dietary salt-induced hypertension: prevention by a combination of N-acetylcysteine and L-arginine |
| Q46931630 | Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation |
| Q91559781 | Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice |
| Q50962692 | Glycated albumin modifies platelet adhesion and aggregation responses. |
| Q38756562 | Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications |
| Q50218012 | High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. |
| Q33302856 | Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia |
| Q24323192 | Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42 |
| Q57703114 | Involvement of membrane type 1-matrix metalloproteinase (MT1-MMP) in RAGE activation signaling pathways |
| Q41975172 | Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers? |
| Q46468830 | Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells |
| Q24558912 | Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily |
| Q38363926 | Nepsilon-(Carboxymethyl)lysine induces gamma-glutamylcysteine synthetase in RAW264.7 cells |
| Q37990618 | Novel pathways and therapies in experimental diabetic atherosclerosis |
| Q44640723 | Oleate, not ligands of the receptor for advanced glycation end-products, promotes proliferation of human arterial smooth muscle cells |
| Q42575063 | Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection |
| Q36891939 | Oxidative stress, AGE, and atherosclerosis |
| Q36320564 | Pathobiology and cell interactions of platelets in diabetes |
| Q36065338 | Pathophysiology and Medical Treatment of Carotid Artery Stenosis |
| Q34471346 | Peptide aptamers: development and applications |
| Q40708169 | Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties |
| Q40200491 | Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with Type 1 diabetes |
| Q34375738 | Proinflammatory S100 proteins in arthritis and autoimmune disease |
| Q36320548 | RAGE and its ligands: a lasting memory in diabetic complications? |
| Q36969021 | RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases |
| Q37860348 | RAGE biology, atherosclerosis and diabetes |
| Q38094691 | RAGE regulation and signaling in inflammation and beyond. |
| Q33346824 | RAGE signaling in inflammation and arterial aging |
| Q42178404 | RAGE signaling mediates post-injury arterial neointima formation by suppression of liver kinase B1 and AMPK activity |
| Q35854488 | RAGE: a novel target for drug intervention in diabetic vascular disease |
| Q37972674 | Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications |
| Q40899986 | Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response |
| Q35875904 | Receptor for advanced glycation end products involved in circulating endothelial cells release from human coronary endothelial cells induced by C-reactive protein. |
| Q41926813 | Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis |
| Q37373486 | Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. |
| Q34586849 | Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes |
| Q35009768 | Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings |
| Q28388086 | Recovery from volumetric muscle loss injury: A comparison between young and aged rats |
| Q35221896 | Reduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme. |
| Q33946405 | Regulation of S100B in white adipose tissue by obesity in mice |
| Q27003423 | Role of advanced glycation end products in cellular signaling |
| Q36943327 | Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications |
| Q24318401 | S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells |
| Q46745779 | S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. |
| Q40126438 | Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein |
| Q39955806 | Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). |
| Q38686477 | Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. |
| Q37424029 | Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation |
| Q47094524 | The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases |
| Q37091107 | The AGE/RAGE axis in diabetes-accelerated atherosclerosis. |
| Q34567914 | The Protective Effect of Beraprost Sodium on Diabetic Cardiomyopathy through the Inhibition of the p38 MAPK Signaling Pathway in High-Fat-Induced SD Rats |
| Q36787569 | The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications |
| Q91221740 | The dual effect of C-peptide on cellular activation and atherosclerosis: Protective or not? |
| Q42037633 | The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment |
| Q47701882 | The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia |
| Q35896110 | The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study |
| Q37412673 | The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease |
| Q37798969 | Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention |
| Q37618822 | Tissue factor: beyond coagulation in the cardiovascular system |
| Q46495572 | Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients |
| Q36245387 | Understanding RAGE, the receptor for advanced glycation end products |
| Q80968903 | Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis |
| Q36514906 | Uremic Toxicity of Advanced Glycation End Products in CKD. |
| Q37636453 | Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms |
| Q81393241 | [Maillard reaction products in food as pro-inflammatory and pro-arteriosclerotic factors of degenerative diseases] |
| Q84099831 | [Urosepsis and treatment] |
Search more.